Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X MSCI Argentina ETF (ARGT) vs Mesoblast Limited (MESO) Price & Performance

Global X MSCI Argentina ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Global X MSCI Argentina ETF vs Mesoblast Limited — how do they compare? Global X MSCI Argentina ETF trades at $94.69, while Mesoblast Limited trades at $16.34 (market cap $2.00B). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

ARGTMESO
Sector
Broad Market / FactorTechnology
52-Week High
$102.94$20.96
52-Week Low
$67.55$10.96
Market Cap
$2.00B
Enterprise Value
$2.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X MSCI Argentina ETF

ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.

The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.

Mesoblast Limited

MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.

The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO